Pomer S, Thiele R, Staehler G, Drehmer I, Löhrke H, Schirrmacher V
Abteilung Urologie, Universität Heidelberg.
Urologe A. 1995 May;34(3):215-20.
Interleukin 2 (IL2) production is known to bypass T-helper-cell function in the generation of an antitumour response. The present analysis was designed to assess the effects of application of renal cancer vaccine with and without IL2 on delayed-type hypersensitivity (DTH) skin responses to the vaccine itself and tumour cell challenge. The renal cancer vaccine consisted of Newcastle disease virus (NDV)-infected autologous irradiated tumour cells and topical application of low-dose rIL2 (75,000 Cetus units). As a result, the coadministration of a supplement of rIL2 proved to be important for augmentation of DTH responsiveness to tumour cell challenge. Patients with aneuploid tumours vaccinated without rIL2 developed an anergy to the vaccine throughout vaccination. This effect could be reversed by the topical coapplication of this cytokine. While the treatment of renal cancer patients with IL2-based immunotherapy regimens appears to be effective in advanced renal cell carcinoma the IL2-supplemented vaccines should be tested to assess their benefit in the situation of "minimal disease" after surgery especially in high-risk patients with aneuploid tumours.
已知白细胞介素2（IL2）在产生抗肿瘤反应过程中可绕过辅助性T细胞功能。本分析旨在评估使用和不使用IL2的肾癌疫苗对疫苗本身及肿瘤细胞攻击的迟发型超敏反应（DTH）皮肤反应的影响。肾癌疫苗由新城疫病毒（NDV）感染的自体照射肿瘤细胞和局部应用低剂量重组IL2（75,000西特斯单位）组成。结果表明，补充重组IL2对增强对肿瘤细胞攻击的DTH反应性很重要。接种不含重组IL2的非整倍体肿瘤患者在整个接种过程中对疫苗产生了无反应性。这种效应可通过局部联合应用这种细胞因子来逆转。虽然基于IL2的免疫治疗方案治疗肾癌患者在晚期肾细胞癌中似乎有效，但应测试补充IL2的疫苗，以评估其在手术后“微小疾病”情况下的益处，特别是在非整倍体肿瘤的高危患者中。
